ID Week 2022
An Inhaled IFN-ß Treatment May Decrease Risk for Long COVID-19 Symptoms
Patients with COVID-19 who required low-flow oxygen supplementation were randomly assigned to receive either SNG001 (n=314) or placebo (n=309) once daily for 14 days.